Testing a new treatment for high-risk colon cancer after surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment approach for people with certain high-risk colon cancers (stage II or III in the upper colon) after surgery. It aims to see if adding a study drug can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colon cancer that is stage III or high-risk stage II, and it must be located in the upper part of the colon (at least 12 cm from the anus).
- You need to have a sample of your tumor preserved in paraffin (FFPE) available for testing.
- You must be well enough to do daily activities (ECOG score 0 or 1).
- You cannot have had any chemotherapy or radiation before your surgery.
- You cannot have had another cancer in the past 5 years (except for some skin cancers or very early cancers).
- You must be willing to use effective contraception if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving mFOLFIRINOX chemotherapy after curative surgery for people with high-risk stage III colon cancer. It aims to lower the chance that cancer comes back.
This trial tests a new combination of two chemotherapy drugs (CAPOX) plus an immunotherapy drug (tislelizumab) before surgery for high-risk colon cancer that has not spread. It aims to see if adding tislelizumab helps shrink the tumor and lower the chance of the cancer coming back.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
This trial is testing three different combinations of existing and new drugs for advanced or metastatic colorectal cancer that hasn't improved with standard treatments or has spread to the liver. The goal is to see which combination works best and is safe for patients like you.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
Hear when a new Colon Cancer Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.